跳至主要内容
临床试验/NCT02241772
NCT02241772已完成1 期

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

Xention Ltd1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Xention Ltd
入组人数
42
试验地点
1
主要终点
To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.

研究概览

简要总结

A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels

排除标准

  • Clinically significant medical history
  • Abnormal laboratory results (other than lipid levels) or vital signs
  • Receiving any other drug therapy

研究组 & 干预措施

10mg TA-8995

Experimental

10mg TA-8995 once daily

干预措施: TA-8995 (Drug)

2.5mg TA-8995

Experimental

2.5mg TA-8995 once daily

干预措施: TA-8995 (Drug)

Placebo to TA-8995

Placebo Comparator

Placebo to TA-8995 once daily.

干预措施: Placebo (Drug)

结局指标

主要结局

To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.

时间窗: 12 weeks

次要结局

  • Number of participants with adverse events(12 weeks)

研究者

发起方
Xention Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验